These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21540324)

  • 1. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.
    Schenk JM; Kristal AR; Arnold KB; Tangen CM; Neuhouser ML; Lin DW; White E; Thompson IM
    Am J Epidemiol; 2011 Jun; 173(12):1419-28. PubMed ID: 21540324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Finasteride reduces the risk of incident clinical benign prostatic hyperplasia.
    Parsons JK; Schenk JM; Arnold KB; Messer K; Till C; Thompson IM; Kristal AR; ;
    Eur Urol; 2012 Aug; 62(2):234-41. PubMed ID: 22459892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.
    Kristal AR; Schenk JM; Song Y; Arnold KB; Neuhouser ML; Goodman PJ; Lin DW; Stanczyk FZ; Thompson IM
    Am J Epidemiol; 2008 Dec; 168(12):1416-24. PubMed ID: 18945688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
    Roehrborn CG; Casabé A; Glina S; Sorsaburu S; Henneges C; Viktrup L
    Int J Urol; 2015 Jun; 22(6):582-7. PubMed ID: 25827166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
    Schenk JM; Kristal AR; Neuhouser ML; Tangen CM; White E; Lin DW; Thompson IM
    Prostate; 2009 Sep; 69(12):1303-11. PubMed ID: 19475640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
    Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Finasteride in the treatment of benign prostatic hyperplasia].
    Ząbkowski T
    Urologe A; 2012 Jul; 51(7):982-6. PubMed ID: 22772497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
    Logan YT; Belgeri MT
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
    Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
    Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia.
    Liang JA; Sun LM; Lin MC; Chang SN; Sung FC; Muo CH; Kao CH
    Oncologist; 2012; 17(7):986-91. PubMed ID: 22723508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-alpha-reductase Inhibitors for prostate cancer prevention.
    Wilt TJ; MacDonald R; Hagerty K; Schellhammer P; Kramer BS
    Cochrane Database Syst Rev; 2008 Apr; (2):CD007091. PubMed ID: 18425978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Breyer BN; Huang WY; Rabkin CS; Alderete JF; Pakpahan R; Beason TS; Kenfield SA; Mabie J; Ragard L; Wolin KY; Grubb RL; Andriole GL; Sutcliffe S
    BJU Int; 2016 Jan; 117(1):145-54. PubMed ID: 25601300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
    Schenk JM; Calip GS; Tangen CM; Goodman P; Parsons JK; Thompson IM; Kristal AR
    Am J Epidemiol; 2012 Jul; 176(2):156-63. PubMed ID: 22759721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
    Kristal AR; Arnold KB; Schenk JM; Neuhouser ML; Goodman P; Penson DF; Thompson IM
    Am J Epidemiol; 2008 Apr; 167(8):925-34. PubMed ID: 18263602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial.
    Kaplan SA; Lee JY; Meehan AG; Kusek JW;
    J Urol; 2011 Apr; 185(4):1369-73. PubMed ID: 21334655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
    Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
    BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BPH: a tell-tale sign of prostate cancer? Results from the Prostate Cancer and Environment Study (PROtEuS).
    Boehm K; Valdivieso R; Meskawi M; Larcher A; Sun M; Sosa J; Blanc-Lapierre A; Weiss D; Graefen M; Saad F; Parent MÉ; Karakiewicz PI
    World J Urol; 2015 Dec; 33(12):2063-9. PubMed ID: 25824539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study.
    Yang XJ; Lecksell K; Short K; Gottesman J; Peterson L; Bannow J; Schellhammer PF; Fitch WP; Hodge GB; Parra R; Rouse S; Waldstreicher J; Epstein JI
    Urology; 1999 Apr; 53(4):696-700. PubMed ID: 10197843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.